Compas on July 27 announced a rebranding that reflects future growth of the organization and expansion of its capabilities.
One of the eagerly anticipated presentations at the 2021 Alzheimer’s Association International Conference in Denver and virtually is Biogen and the company’s partner Eisai on their controversial drug Aduhelm (aducanumab). Biogen is also presenting new data on a different Alzheimer’s drug with another partner, Ionis Pharmaceuticals.
California-based biopharmaceutical firm BridgeBio Pharma announced a funding collaboration with Bristol Myers Squibb to evaluate a potential treatment for patients with difficult-to-treat cancers.
The U.S. Centers for Disease Control and Prevention is set on July 27 to recommend fully vaccinated Americans wear masks indoors in at least some instances, as the more highly transmissible Delta variant of the coronavirus has led to a surge in infections, sources said.
After an earlier rejection from the U.S. Food and Drug Administration, Merck’s vaunted checkpoint inhibitor Keytruda won approval for the treatment of patients with high-risk, early-stage triple-negative breast cancer.
Purdue Pharma LP said on Tuesday that creditors voted in favor of the company’s reorganization plan that would provide billions of dollars to the governments that sued the OxyContin maker for its role in the U.S. opioid crisis.
